Crescent Biopharma Inc(CBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CBIO Crescent Biopharma Inc

休市中 01-16 16:00:00 EST

13.51

+1.01

+8.08%

盘后13.51

+0.000.00%

17:29 EST

最高13.93	最低12.42	成交量16.94万
今开12.58	昨收12.50	日振幅12.08%
总市值3.72亿	流通市值1.47亿	总股本2,756万
成交额226.57万	换手率1.56%	流通股本1,087万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CBIO","market":"US","secType":"STK","nameCN":"Crescent Biopharma Inc","latestPrice":13.51,"timestamp":1768597200000,"preClose":12.5,"halted":0,"volume":169448,"hourTrading":{"tag":"盘后","latestPrice":13.51,"preClose":13.51,"latestTime":"17:29 EST","volume":2403,"amount":32464.56,"timestamp":1768602595628,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.08079999999999998,"floatShares":10871000,"shares":27556800,"eps":-21.9706,"marketStatus":"休市中","change":1.01,"latestTime":"01-16 16:00:00 EST","open":12.58,"high":13.93,"low":12.42,"amount":2265695.13868,"amplitude":0.1208,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-21.9706,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1768899600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1389330000000,"exchange":"NASDAQ","adjPreClose":12.5,"postHourTrading":{"tag":"盘后","latestPrice":13.51,"preClose":13.51,"latestTime":"17:29 EST","volume":2403,"amount":32464.56,"timestamp":1768602595628,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.272791187227831,"impliedVol":2.2495,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/CBIO","defaultTab":"news","newsList":[{"id":"1158200264","title":"新闻稿：Crescent Biopharma公布诱导奖励授予情况","url":"https://stock-news.laohu8.com/highlight/detail?id=1158200264","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158200264?lang=zh_cn&edition=full","pubTime":"2025-12-19 05:18","pubTimestamp":1766092728,"startTime":"0","endTime":"0","summary":"马萨诸塞州沃尔瑟姆，2025年12月18日-- Crescent Biopharma, Inc.，一家致力于快速推进癌症患者下一波治疗方案的生物技术公司，今天宣布其独立董事会批准向三名非执行员工授予总计129,626股公司普通股的期权作为《Crescent Biopharma, Inc. 2025就业诱导激励奖励计划》下的股权诱导奖励。该期权于2025年12月13日批准，2025年12月15日授予，并且对于每位员工接受Crescent的工作至关重要，符合纳斯达克上市规则5635。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBIO","BK4139"],"gpt_icon":0},{"id":"1137740447","title":"Crescent Biopharma 宣布与 Kelun-Biotech 达成重大合作，并进行 1.85 亿美元私人配售，推动和扩展全球下一代实体肿瘤治疗药物的管道","url":"https://stock-news.laohu8.com/highlight/detail?id=1137740447","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137740447?lang=zh_cn&edition=full","pubTime":"2025-12-04 19:36","pubTimestamp":1764848174,"startTime":"0","endTime":"0","summary":"Crescent Biopharma 宣布与 Kelun-Biotech 达成重大合作，并进行 1.85 亿美元私人配售，推动和扩展全球下一代实体肿瘤治疗药物的管道。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CBIO"],"gpt_icon":0},{"id":"1115537632","title":"Crescent Biopharma Inc - 将获得2000万美元的预付款，以及来自科伦博泰生物的最高3000万美元的额外里程碑款项","url":"https://stock-news.laohu8.com/highlight/detail?id=1115537632","media":"美股速递","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115537632?lang=zh_cn&edition=full","pubTime":"2025-12-04 19:32","pubTimestamp":1764847944,"startTime":"0","endTime":"0","summary":"Crescent Biopharma Inc - 将获得2000万美元的预付款，以及来自科伦博泰生物的最高3000万美元的额外里程碑款项","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["002422","CBIO","LU1064130708.USD","BK1161","LU1934453819.USD","BK0060","06990","BK0239","LU1979443071.USD","LU0196878994.USD","LU1064131003.USD","BK4139","LU2148510915.USD"],"gpt_icon":0},{"id":"1126942018","title":"Crescent Biopharma Inc - 科伦博泰生物-B将获得8000万美元的预付款，以及来自Crescent的最高达12.5亿美元的额外里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1126942018","media":"美股速递","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126942018?lang=zh_cn&edition=full","pubTime":"2025-12-04 19:32","pubTimestamp":1764847941,"startTime":"0","endTime":"0","summary":"Crescent Biopharma Inc - 科伦博泰生物-B将获得8000万美元的预付款，以及来自Crescent的最高达12.5亿美元的额外里程碑付款","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064131003.USD","BK4139","CBIO","BK0060","BK0239","06990","BK1161","LU0196878994.USD","LU1064130708.USD","LU1934453819.USD","LU1979443071.USD","002422","LU2148510915.USD"],"gpt_icon":0},{"id":"1115079280","title":"科伦药业与Crescent Biopharma达成战略合作，共同开发及商业化新型抗肿瘤疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1115079280","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115079280?lang=zh_cn&edition=full","pubTime":"2025-12-04 19:30","pubTimestamp":1764847815,"startTime":"0","endTime":"0","summary":"科伦药业与Crescent Biopharma达成战略合作，共同开发及商业化新型抗肿瘤疗法","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["002422","BK0060","LU1979443071.USD","BK0239","06990","LU0196878994.USD","BK4139","LU1064130708.USD","LU1064131003.USD","LU2148510915.USD","LU1934453819.USD","BK1161","CBIO"],"gpt_icon":0},{"id":"1118946436","title":"Crescent Biopharma：截至9月30日现金为1.333亿美元，预计可支持运营至2027年","url":"https://stock-news.laohu8.com/highlight/detail?id=1118946436","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118946436?lang=zh_cn&edition=full","pubTime":"2025-11-06 20:37","pubTimestamp":1762432661,"startTime":"0","endTime":"0","summary":"Crescent Biopharma：截至9月30日现金为1.333亿美元，预计可支持运营至2027年","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CBIO"],"gpt_icon":0},{"id":"2571337076","title":"凯赛生物拟推2025年员工持股计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2571337076","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571337076?lang=zh_cn&edition=full","pubTime":"2025-09-29 22:11","pubTimestamp":1759155072,"startTime":"0","endTime":"0","summary":"员工持股计划初始设立时持有人总人数不超过155人，其中董事、高级管理人员共6人，具体参加人数根据员工实际缴款情况确定。员工持股计划拟持有的标的股票数量不超过130.00万股，约占员工持股计划草案公布时公司股本总额的0.18%。为满足公司可持续发展的需要及不断吸引和留住优秀人才，员工持股计划拟预留15.00万股作为预留份额，占员工持股计划股票总数的11.54%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250929221421a44c8e96&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250929221421a44c8e96&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CBIO","BK4139"],"gpt_icon":0},{"id":"2556889051","title":"凯赛生物：累计回购23万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2556889051","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556889051?lang=zh_cn&edition=full","pubTime":"2025-08-01 18:54","pubTimestamp":1754045656,"startTime":"0","endTime":"0","summary":"格隆汇8月1日丨凯赛生物(688065.SH)公布，2025年7月31日，公司通过上海证券交易所交易系统以集中竞价交易方式回购公司股份230,366股,占公司总股本721,289,794股的比例为0.0319%。回购成交的最高价为53.40元/股，最低价为44.08元/股，支付的资金总额为人民币10,497,716.71元（不含印花税、交易佣金等交易费用)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250801185648a46f9b1b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250801185648a46f9b1b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CBIO","BK4139"],"gpt_icon":0},{"id":"2550966326","title":"凯赛生物获得发明专利授权：“重组核酸序列、重组表达载体以及基因工程菌”","url":"https://stock-news.laohu8.com/highlight/detail?id=2550966326","media":"证券之星企业动态","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550966326?lang=zh_cn&edition=full","pubTime":"2025-07-12 02:42","pubTimestamp":1752259353,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示凯赛生物新获得一项发明专利授权，专利名为“重组核酸序列、重组表达载体以及基因工程菌”，专利申请号为CN202111155453.8，授权日为2025年7月11日。其中，所述重组核酸序列包括串联启动子、赖氨酸脱羧酶基因以及增强细胞耐受压力的基因，所述串联启动子包括piclR启动子和稳定期特异性启动子。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250712025655953f1c89&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250712025655953f1c89&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CBIO","BK4139"],"gpt_icon":0},{"id":"2379512739","title":"凯赛生物：截至10月31日已回购54.9236万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2379512739","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2379512739?lang=zh_cn&edition=full","pubTime":"2023-10-31 18:12","pubTimestamp":1698747120,"startTime":"0","endTime":"0","summary":"证券日报网讯 10月31日晚间，凯赛生物发布公告称，截至2023年10月31日，公司通过上海证券交易所交易系统以集中竞价交易方式回购公司股份54.9236万股，占公司总股本58337.8039万股的比例为0.0941%。回购成交的最高价为57.37元/股，最低价为52.90元/股，支付的资金总额人民币3057.0741万元（不含印花税、交易佣金等交易费用）。（编辑 何帆）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023103118311783989b56&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023103118311783989b56&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688065","CBIO","GYRE","BK0208"],"gpt_icon":0},{"id":"2379198955","title":"凯赛生物：累计回购约55万股 占比0.0941%","url":"https://stock-news.laohu8.com/highlight/detail?id=2379198955","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2379198955?lang=zh_cn&edition=full","pubTime":"2023-10-31 17:37","pubTimestamp":1698745056,"startTime":"0","endTime":"0","summary":"凯赛生物（SH 688065，收盘价：53.11元）10月31日晚间发布公告称，截至2023年10月31日，公司通过上海证券交易所交易系统以集中竞价交易方式回购公司股份约55万股，占公司总股本约5.83亿股的比例为0.0941%。2022年1至12月份，凯赛生物的营业收入构成为：合成生物材料行业占比95.55%。凯赛生物的董事长、总裁均是XIUCAI LIU(刘修才)，男，66岁，学历背景为博士。截至发稿，凯赛生物市值为310亿元。文章来源：每日经济新闻原标题：凯赛生物：累计回购约55万股，占比0.0941%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023103117393083d61d06&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023103117393083d61d06&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0208","CBIO","GYRE","688065"],"gpt_icon":0},{"id":"2379589096","title":"Catalyst Biosciences Inc盘中异动 大幅上涨7.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2379589096","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2379589096?lang=zh_cn&edition=full","pubTime":"2023-10-30 21:30","pubTimestamp":1698672625,"startTime":"0","endTime":"0","summary":"北京时间2023年10月30日21时30分，Catalyst Biosciences Inc股票出现波动，股价急速拉升7.88%。Catalyst Biosciences Inc股票所在的生物技术行业中，整体涨幅为0.00%。Catalyst Biosciences Inc公司简介：凯赛生物公司是一家临床阶段生物制药公司。消息层面，截至21时30分，《凯赛生物2023年前三季度净利3.14亿 同比减少35.44%》资讯为影响Catalyst Biosciences Inc的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202310302130258475f4fa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202310302130258475f4fa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","GYRE","CBIO"],"gpt_icon":0},{"id":"2379304977","title":"凯赛生物2023年前三季度净利3.14亿 同比减少35.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2379304977","media":"挖贝网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2379304977?lang=zh_cn&edition=full","pubTime":"2023-10-30 19:01","pubTimestamp":1698663690,"startTime":"0","endTime":"0","summary":"挖贝网2023年10月30日，凯赛生物 近日发布2023年前三季度报,报告期内，公司实现营业收入1,565,490,018.66元,同比减少14.81%；归属于上市公司股东的净利润313,885,180.71元，同比减少35.44%。报告期内研发费用126,413,295.65元，上年同期134,754,753.10元，同比减少6.19%。挖贝网资料显示，凯赛生物的主要业务为新型生物基材料的研发、生产及销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023103019034483d2d8f8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023103019034483d2d8f8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GYRE","688065","CBIO","BK4139"],"gpt_icon":0},{"id":"2379307906","title":"凯赛生物：2023年前三季度净利润约3.14亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2379307906","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2379307906?lang=zh_cn&edition=full","pubTime":"2023-10-30 18:57","pubTimestamp":1698663430,"startTime":"0","endTime":"0","summary":"凯赛生物（SH 688065，收盘价：53.78元）10月30日晚间发布三季度业绩公告称，2023年前三季度营收约15.65亿元，同比减少14.81%；归属于上市公司股东的净利润约3.14亿元，同比减少35.44%。2022年1至12月份，凯赛生物的营业收入构成为：合成生物材料行业占比95.55%。凯赛生物的董事长、总裁均是XIUCAI LIU(刘修才)，男，66岁，学历背景为博士。截至发稿，凯赛生物市值为314亿元。文章来源：每日经济新闻原标题：凯赛生物：2023年前三季度净利润约3.14亿元","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023103019100783d2dce7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023103019100783d2dce7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688065","GYRE","CBIO"],"gpt_icon":0},{"id":"2378870508","title":"Catalyst Biosciences Inc盘中异动 早盘急速拉升6.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2378870508","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2378870508?lang=zh_cn&edition=full","pubTime":"2023-10-27 21:43","pubTimestamp":1698414201,"startTime":"0","endTime":"0","summary":"北京时间2023年10月27日21时43分，Catalyst Biosciences Inc股票出现异动，股价大幅拉升6.66%。Catalyst Biosciences Inc股票所在的生物技术行业中，整体跌幅为0.74%。Catalyst Biosciences Inc公司简介：凯赛生物公司是一家临床阶段生物制药公司。消息层面，截至21时43分，《年报季·龙头系列 | 凯赛生物：业绩以及经营效率下滑，估值较低》资讯为影响Catalyst Biosciences Inc的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023102721432383978a74&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023102721432383978a74&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CBIO","GYRE"],"gpt_icon":0},{"id":"2378852295","title":"Catalyst Biosciences Inc盘中异动 大幅拉升7.55%报0.570美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2378852295","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2378852295?lang=zh_cn&edition=full","pubTime":"2023-10-26 21:35","pubTimestamp":1698327329,"startTime":"0","endTime":"0","summary":"北京时间2023年10月26日21时35分，Catalyst Biosciences Inc股票出现波动，股价快速上涨7.55%。Catalyst Biosciences Inc股票所在的生物技术行业中，整体跌幅为0.41%。Catalyst Biosciences Inc公司简介：凯赛生物公司是一家临床阶段生物制药公司。消息层面，截至21时35分，《年报季·龙头系列 | 凯赛生物：业绩以及经营效率下滑，估值较低》资讯为影响Catalyst Biosciences Inc的重要信息。凯赛生物2023半年报A股排名1653，较上季度排名提高，较去年同期排名大幅下滑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023102621353082ff2eda&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023102621353082ff2eda&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","GYRE","CBIO"],"gpt_icon":0},{"id":"2378041090","title":"Catalyst Biosciences Inc盘中异动 早盘大幅拉升6.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2378041090","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2378041090?lang=zh_cn&edition=full","pubTime":"2023-10-25 21:46","pubTimestamp":1698241612,"startTime":"0","endTime":"0","summary":"北京时间2023年10月25日21时46分，Catalyst Biosciences Inc股票出现异动，股价快速上涨6.68%。Catalyst Biosciences Inc股票所在的生物技术行业中，整体跌幅为0.99%。Catalyst Biosciences Inc公司简介：凯赛生物公司是一家临床阶段生物制药公司。消息层面，截至21时46分，《年报季·龙头系列 | 凯赛生物：业绩以及经营效率下滑，估值较低》资讯为影响Catalyst Biosciences Inc的重要信息。凯赛生物2023半年报A股排名1653，较上季度排名提高，较去年同期排名大幅下滑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202310252146538396bdb5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202310252146538396bdb5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CBIO","BK4139","GYRE"],"gpt_icon":0},{"id":"2378029061","title":"年报季·龙头系列 | 凯赛生物：业绩以及经营效率下滑，估值较低（2023半年报）","url":"https://stock-news.laohu8.com/highlight/detail?id=2378029061","media":"和讯网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2378029061?lang=zh_cn&edition=full","pubTime":"2023-10-25 10:58","pubTimestamp":1698202722,"startTime":"0","endTime":"0","summary":"凯赛生物2023半年报行业排名107，较上季度排名提高，较去年同期排名下滑。四核心财务特征2023半年报凯赛生物净利润2.64亿元，与2022半年报相比，净利润快速下滑。2023半年报凯赛生物经营资产报酬率0.68%。凯赛生物2023半年报经营活动现金净流入3.24亿元，较2023半年报减少0.37亿元，2021年报到本期经营活动累计产生净流入17.22亿元。2023半年报凯赛生物经营活动与投资活动资金缺口5.45亿元较2022半年报减少12.62亿元，缺口迅速缩小。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202310251110268221ab37&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202310251110268221ab37&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688065","GYRE","CBIO","BK0208"],"gpt_icon":0},{"id":"2377508285","title":"Catalyst Biosciences Inc股价重挫10.84% 市值跌74.44万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2377508285","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2377508285?lang=zh_cn&edition=full","pubTime":"2023-10-24 21:35","pubTimestamp":1698154556,"startTime":"0","endTime":"0","summary":"北京时间2023年10月24日21时35分，Catalyst Biosciences Inc股票出现异动，股价急速下跌10.84%。截至发稿，该股报0.416美元/股，成交量6.7714万股，换手率0.18%，振幅9.33%。Catalyst Biosciences Inc股票所在的生物技术行业中，整体涨幅为0.61%。其相关个股中，联拓生物、Immunitybio Inc、Maia Biotechnology Inc涨幅较大，Transcode Therapeutics Inc、Maia Biotechnology Inc、联拓生物较为活跃，换手率分别为55.27%、18.59%、12.25%，振幅较大的相关个股有Immunitybio Inc、Eiger Biopharmaceuticals Inc、联拓生物，振幅分别为17.53%、15.90%、15.76%。Catalyst Biosciences Inc公司简介：凯赛生物公司是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023102421355683965f51&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023102421355683965f51&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","GYRE","CBIO"],"gpt_icon":0},{"id":"2377716410","title":"Catalyst Biosciences Inc盘中异动 快速跳水6.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2377716410","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2377716410?lang=zh_cn&edition=full","pubTime":"2023-10-23 21:32","pubTimestamp":1698067945,"startTime":"0","endTime":"0","summary":"北京时间2023年10月23日21时32分，Catalyst Biosciences Inc股票出现波动，股价快速下跌6.94%。Catalyst Biosciences Inc股票所在的生物技术行业中，整体涨幅为0.19%。Catalyst Biosciences Inc公司简介：凯赛生物公司是一家临床阶段生物制药公司。消息层面，截至21时32分，《康蒂尼药业与CATALYST BIOSCIENCES,INC.合并赴美IPO获中国证监会备案 拟在纳斯达克上市》资讯为影响Catalyst Biosciences Inc的重要信息。同时，公司完成境外发行上市后15个工作日内，应通过中国证监会备案管理信息系统报告发行上市情况。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231023213227821ca7e1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231023213227821ca7e1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CBIO"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.glycomimetics.com","stockEarnings":[{"period":"1week","weight":0.2521},{"period":"1month","weight":0.0817},{"period":"3month","weight":0.0774},{"period":"6month","weight":0.0127},{"period":"1year","weight":-0.4643},{"period":"ytd","weight":0.1391}],"compareEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":0.0302},{"period":"3month","weight":0.041},{"period":"6month","weight":0.1021},{"period":"1year","weight":0.1691},{"period":"ytd","weight":0.0143}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Crescent Biopharma, Inc.是一家开曼群岛公司，于2003年在特拉华州注册成立，是一家后期临床生物技术公司，致力于通过抑制细胞表面发生的碳水化合物相互作用来改善癌症和炎症性疾病患者的生活。该公司正在开发一种专有的糖模拟物管道，糖模拟物是模仿碳水化合物结构的小分子，参与抑制碳水化合物疾病相关功能的重要生物过程。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.029109},{"month":2,"riseRate":0.583333,"avgChangeRate":-0.015525},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.053963},{"month":4,"riseRate":0.416667,"avgChangeRate":-0.063712},{"month":5,"riseRate":0.5,"avgChangeRate":0.092337},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.022838},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.058163},{"month":8,"riseRate":0.416667,"avgChangeRate":-0.053488},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.058271},{"month":10,"riseRate":0.5,"avgChangeRate":0.107936},{"month":11,"riseRate":0.75,"avgChangeRate":0.290074},{"month":12,"riseRate":0.25,"avgChangeRate":-0.030216}],"exchange":"NASDAQ","name":"Crescent Biopharma Inc","nameEN":"Crescent Biopharma Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Crescent Biopharma Inc(CBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Crescent Biopharma Inc(CBIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Crescent Biopharma Inc,CBIO,Crescent Biopharma Inc股票,Crescent Biopharma Inc股票老虎,Crescent Biopharma Inc股票老虎国际,Crescent Biopharma Inc行情,Crescent Biopharma Inc股票行情,Crescent Biopharma Inc股价,Crescent Biopharma Inc股市,Crescent Biopharma Inc股票价格,Crescent Biopharma Inc股票交易,Crescent Biopharma Inc股票购买,Crescent Biopharma Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Crescent Biopharma Inc(CBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Crescent Biopharma Inc(CBIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}